HELX — Franklin Genomic Advancements ETF
Data updated: 2026-06-12
HELX — Franklin Genomic Advancements ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $21.45M AUM · 0.50% expense ratio · 22.8% 1-yr return. From SEC regulatory filings.
HELX Fund Overview
HELX — Franklin Genomic Advancements ETF is a US ETF managed by Franklin Templeton ETF Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Franklin Templeton ETF Trust
- Category: United States Health Care Equity
- Assets under management: $21.45M
- 1-year return: 22.8%
- Ticker: HELX
- SEC CIK: 0001655589
- SEC series ID: S000067393
- Share class ID: C000216720
HELX Holdings
Top 10 holdings of Franklin Genomic Advancements ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Guardant Health Inc | 6.77% |
| Natera, Inc. | 6.65% |
| Krystal Biotech Inc | 5.32% |
| United Therapeutics Corporation | 4.64% |
| Insmed Inc | 4.52% |
| Bridgebio Pharma Inc | 4.22% |
| Ligand Pharmaceuticals Incorporated | 3.53% |
| AstraZeneca PLC | 3.40% |
| Adaptive Biotechnologies Corp | 3.12% |
| Vertex Pharmaceuticals Incorporated | 2.99% |
HELX Portfolio Allocation
Asset-class allocation of Franklin Genomic Advancements ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.0% |
HELX Performance
Total returns for HELX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -9.1% |
| 1 year | 22.8% |
| 3 years (annualised) | 2.9% |
| 5 years (annualised) | -5.1% |
HELX Risk Information
Risk metrics for HELX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 21.6%
HELX Costs and Fees
HELX costs about $50 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.50%
- Gross expense ratio: 0.50%
- Portfolio turnover: 33%
- Brokerage commissions: 0.95 bps of average net assets (SEC N-CEN)
HELX Cashflows
Over the 12 months to 2026-03, Franklin Genomic Advancements ETF had net inflows of $7.79M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | $0 |
| 2026-02 | $0 |
| 2026-01 | $1.90M |
| 2025-12 | $0 |
| 2025-11 | $0 |
| 2025-10 | $1.62M |
HELX Debt Constituents
No individual debt constituents are reported in Franklin Genomic Advancements ETF's latest SEC N-PORT filing.
HELX Prospectus and SEC Filings
Official Franklin Genomic Advancements ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.